Featured Research

from universities, journals, and other organizations

Experimental Marburg vaccine prevents disease two days after infection

Date:
June 18, 2010
Source:
NIH/National Institute of Allergy and Infectious Diseases
Summary:
An experimental vaccine developed to prevent outbreaks of Marburg hemorrhagic fever continues to show promise in monkeys as an emergency treatment for accidental exposures to the virus that causes the disease. There is no licensed treatment for Marburg infection, which has a high fatality rate.

Colorized Marburg virus particles viewed with a transmission electron microscope.
Credit: Image courtesy of Dr. Tom Geisbert

An experimental vaccine developed to prevent outbreaks of Marburg hemorrhagic fever continues to show promise in monkeys as an emergency treatment for accidental exposures to the virus that causes the disease. There is no licensed treatment for Marburg infection, which has a high fatality rate.

In a study of rhesus macaques, 5 of 6 monkeys survived a lethal dose of Marburg virus when treated 24 hours after infection, and 2 of 6 survived when treated 48 hours after infection. Because rhesus macaques typically succumb to Marburg infection faster than humans, the post-exposure treatment window might be extended even further in humans, the study authors say.

The study, overseen by a scientific team from the National Institutes of Health and three other groups with expertise in viral hemorrhagic fevers, was posted online by the journal Emerging Infectious Diseases.

Marburg and Ebola are the only members of the filovirus family. They are hemorrhagic fever pathogens, meaning the infection may lead to shock, bleeding and multi-organ failure. According to the World Health Organization, Marburg hemorrhagic fever has a fatality rate of up to 80 percent, while Ebola fever has a fatality rate of up to 90 percent. Confirmed cases of these hemorrhagic fevers have been reported in about a half-dozen African nations, according to the Centers for Disease Control and Prevention. Cases of Marburg have occurred outside Africa, though infrequently. Ebola is not known to be native to other continents, such as North America.

"Developing safe, effective, and rapidly deployable post-exposure treatments for filoviruses is an important scientific priority for our Institute," says Anthony S. Fauci, M.D., director of NIH's National Institute of Allergy and Infectious Diseases (NIAID). "The vaccine used in this study is among several novel approaches to treating filoviruses that show great potential."

In the study, the scientists sought to answer a question that lingered from research they published in 2006: How long after a usually lethal Marburg virus dose could the experimental vaccine be administered and still provide protection? The 2006 study, also conducted in rhesus macaques, showed 100 percent protection, but the vaccine was given within 30 minutes of lethal exposure.

The timing question is particularly relevant for scientists who study this virus under strict biosafety laboratory guidelines. One such scientist is Heinz Feldmann, M.D., Ph.D., chief of the Laboratory of Virology at NIAID's Rocky Mountain Laboratories in Hamilton, Mont. Dr. Feldmann and his colleagues developed the candidate Marburg vaccine while working for the Public Health Agency of Canada. Collaborators on the current study came from that agency, Boston University and the U.S. Army Medical Research Institute of Infectious Diseases, where most of the animal work was done in 2008-09.

The experimental Marburg vaccine is based on a weakened vesicular stomatitis virus (VSV) used to carry and display a component of the Marburg virus. VSV is an infectious disease of horses, cattle and pigs. Dr. Feldmann and his colleagues also have developed a similar experimental VSV-based vaccine against Ebola. Both vaccines are recognized by the same immune cells in the body as Ebola and Marburg viruses, activating the immune system to fight off the target virus.

The fact that three of the rhesus macaques in the current study showed evidence of Marburg virus in periodic blood tests, but later cleared the virus from their systems and survived, is particularly satisfying to Dr. Feldmann and his main collaborator, Tom Geisbert, Ph.D., of Boston University. In addition, 14 days after infection, all of the rhesus macaques that survived showed moderate to high levels of antibodies against Marburg virus. The scientists view this as proof that the vaccine worked as hoped.

"The results demonstrate that the vaccine can interfere with the Marburg infection and activate the immune system, both protecting the animals and preventing the virus from spreading," says Dr. Feldmann. Dr. Geisbert believes the study data justify rapid development of VSV-based vaccines for the treatment of filovirus-infected patients either in outbreaks or accidental laboratory exposures.

In 2009, Drs. Feldmann and Geisbert were part of an international group of experts that recommended using the same post-exposure treatment strategy for the first time in a human. A researcher who accidentally was stuck with an Ebola-contaminated needle voluntarily received the experimental VSV Ebola vaccine 40 hours after the exposure. The researcher, who never showed signs of infection, survived. The scientists have not yet found a way to determine whether an Ebola infection occurred in this case, however, and whether the vaccine played a role in the outcome.


Story Source:

The above story is based on materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.


Journal References:

  1. T Geisbert et al. Postexposure treatment of Marburg virus infection. Emerging Infectious Diseases, 2010; DOI: 10.3201/eid1607.100159
  2. K Daddariodicaprio, T Geisbert, U Stroher, J Geisbert, a Grolla, E Fritz, L Fernando, E Kagan, P Jahrling, L Hensley. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. The Lancet, 2006; 367 (9520): 1399 DOI: 10.1016/S0140-6736(06)68546-2
  3. Heinz Feldmann, Steven M. Jones, Kathleen M. Daddario-DiCaprio, Joan B. Geisbert, Ute Strφher, Allen Grolla, Mike Bray, Elizabeth A. Fritz, Lisa Fernando, Friederike Feldmann, Lisa E. Hensley, Thomas W. Geisbert. Effective Post-Exposure Treatment of Ebola Infection. PLoS Pathogens, 2007; 3 (1): e2 DOI: 10.1371/journal.ppat.0030002

Cite This Page:

NIH/National Institute of Allergy and Infectious Diseases. "Experimental Marburg vaccine prevents disease two days after infection." ScienceDaily. ScienceDaily, 18 June 2010. <www.sciencedaily.com/releases/2010/06/100616122114.htm>.
NIH/National Institute of Allergy and Infectious Diseases. (2010, June 18). Experimental Marburg vaccine prevents disease two days after infection. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2010/06/100616122114.htm
NIH/National Institute of Allergy and Infectious Diseases. "Experimental Marburg vaccine prevents disease two days after infection." ScienceDaily. www.sciencedaily.com/releases/2010/06/100616122114.htm (accessed July 30, 2014).

Share This




More Plants & Animals News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Raw: Thousands Flocking to German Crop Circle

Raw: Thousands Flocking to German Crop Circle

AP (July 30, 2014) — Thousands of people are trekking to a Bavarian farmer's field to check out a mysterious set of crop circles. (July 30) Video provided by AP
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) — Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) — At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) — The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:  

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile iPhone Android Web
      Follow Facebook Twitter Google+
      Subscribe RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins